Abstract
Purpose :
To assess visual acuity and low luminance visual acuity in patients with age-related macular degeneration (AMD)
Methods :
The AMD Phenotype and Genotype Study (APGS) was a multi-national, multi-center, observational pilot study. As part of the pilot study a total of enrolled a total of 344 participants ranging from no AMD to late AMD between September 2012 and August 2014. Both visual acuity and low luminance visual acuity measurements were collected for a total of 100 of these participants at the pilot study visit. Best corrected visual acuity (BCVA) was collected using the standard Early Treatment for Diabetic Retinopathy Study (ETDRS) protocol. Low luminance visual acuity (LLVA) measurements were collected using the standard ETDRS protocol using a 2.0 log to the base 10 neutral density filter over the best correction. Participants were also administered a low vision questionnaire.
Results :
A total of 198 eyes of 100 participants are included in this report. There was a strong correlation between BCVA and LLVA (r = 0.85; p-value < 0.001). The mean ± standard error (SE) in LLVA for eyes with no AMD; intermediate AMD; reticular drusen; NV AMD and geographic atrophy (GA) were 71.9 ± 1.5; 67.6 ± 1.7; 57.3 ± 4.8; 49.9 ± 3.9; and 33.7 ± 11.9, respectively. Eyes with reticular drusen, NV AMD and GA had statistically significantly mean lower LLA compared to control eyes (p-values = 0.004; <0.001; and 0.001, respectively). Low-luminance deficit (LLD) was calculated as the difference between LLVA and BCVA. The mean LLD for eyes with no AMD; intermediate AMD; reticular drusen; NV AMD; and geographic atrophy (GA) were 13.5 ± 0.9; 16.3 ± 1.4; 18.0 ± 2.1; 13.5 ± 2.3; and 27.1 ± 7.1, respectively. There was a significant difference in mean LLD compared to control eyes for eyes with GA.
Conclusions :
These data provide information in determining the prognostic value of measuring low luminance visual acuity in patients with AMD.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.